REG - Polarean Imaging PLC - Chest coil passes Philips compatibility testing

Polarean ImagingAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251201:nRSA5089Ja&default-theme=true

RNS Number : 5089J  Polarean Imaging PLC  01 December 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

XENOVIEW® 3T coil passes Philips compatibility testing

Polarean's FDA cleared coil achieves important milestone, expanding clinical
reach

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in functional Magnetic Resonance Imaging ("MRI") of the
lungs, announces that its FDA-cleared XENOVIEW® 3T Chest Coil has
successfully completed compatibility testing conducted by Philips (Philips
Medical Systems Nederland B.V.) and is now confirmed for use with Philips'
latest 3T MRI platforms.

 

Following extensive validation by Philips, the XENOVIEW® 3T Chest Coil is now
confirmed for integration with Philips MRI systems starting in early 2026,
including 3.0T platforms such as the MR 7700
(https://acc.philips.co.uk/healthcare/resources/landing/mr-7700) and Ingenia
Elition X
(https://acc.philips.co.uk/healthcare/resources/landing/the-next-mr-wave/ingenia-elition)
, along with their associated upgrade pathways. Building on Philips'
introduction of Xenon MRI compatibility in 2022 with the MR 7700, the addition
of the Polarean XENOVIEW 3T Chest Coil expands access to advanced pulmonary
imaging and supports a new era of functional lung assessment. This
confirmation, building on the coil's FDA clearance in 2024, positions the
technology for rapid clinical adoption and revenue generation. The XENOVIEW 3T
Chest Coil enables healthcare providers to seamlessly adopt advanced
functional lung ventilation imaging, supporting broader clinical adoption and
advancing the Company's commitment to innovation in pulmonary imaging.

 

This milestone marks a major advance in scaling Polarean's Xenon MRI
technology across a major global installed base and enables clinical and
research sites using Philips MRI systems to incorporate non-invasive,
quantitative assessments of lung function as part of routine care and
research. Following this, Polarean is well positioned to accelerate adoption,
expand market penetration and enhance significant commercial and clinical
value worldwide.

 

Christopher von Jako, Ph.D., Chief Executive Officer of Polarean commented:
"This milestone marks another important advancement in our vision to optimise
lung health and prevent avoidable loss by illuminating hidden disease.
Compatibility with Philips' state-of-the-art MRI platforms greatly broadens
the accessibility of Xenon MRI and will help more hospitals and imaging
centres adopt this powerful technology. Equally significant, our FDA-cleared
coil's seamless integration with Philips systems positions us to drive
adoption by reducing workflow complexity for clinicians, accelerating market
penetration and unlocking growth opportunities."

 

Gwenael Herigault, Global MR Clinical Leader at Philips commented: "The
compatibility of Polarean's FDA-cleared XENOVIEW® 3T Chest Coil with Philips'
3T MRI systems reinforces our shared goal of expanding the capabilities of MRI
to deliver deeper clinical insights. Together, we're enabling clinicians to
access advanced lung imaging tools that help improve diagnostic confidence and
patient care."

 

The compatibility statement confirms that the FDA-cleared XENOVIEW 3T Chest
Coil can be used with Philips MR 7700, Ingenia Elition X, and compatible
software upgrade configurations from 2026 onwards. This development
significantly expands the potential reach of Polarean's technology and
supports its goal of making functional lung MRI more widely available to
clinicians and patients worldwide.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018.

 

 

 

Enquiries:

 

 Polarean Imaging plc                                                  www.polarean.com
                                                                       (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean.com)
                                                                       / www.polarean-ir.com
                                                                       (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean-ir.com)
                                                                         
 Christopher von Jako, Ph.D., Chief Executive Officer                                                   Via Walbrook PR  

 Charles Osborne, Chief Financial Officer                                                                 
                                                                                                                                          
 Stifel (NOMAD and Sole Corporate Broker)                                                                                                +44 (0)20 7710 7600 
 Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good                                                                                                                    
                                                                        
 Walbrook PR               Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Anna Dunphy / Paul McManus / Marcus Ulker             Mob: +44 (0)7876741001 / +44 (0) 7980541893 / +44 (0)7867984 082

 

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform.

 

For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

XENOVIEW® IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 6 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.xenoview.net
(http://www.xenoview.net) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZMZMVRFGKZM



            Copyright 2019 Regulatory News Service, all rights reserved